Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
  • A61P5/26—Androgens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
  • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems

Definitions

• the present invention relates generally to novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs).
• IAPs Apoptosis Proteins
• the present invention includes novel compounds, novel compositions, methods of their use and methods of their manufacture, where such compounds are generally pharmacologically useful as agents in therapies whose mechanism of action rely on the inhibition of the Smac/IAP interaction, and more particularly useful in therapies for the treatment of proliferative diseases, including cancer.
• Programmed cell death plays a critical role in regulating cell number and in eliminating stressed or damaged cells from normal tissues. Indeed, the network of apoptotic signaling mechanisms inherent in most cell types provides a major barrier to the development and progression of human cancer. Since most commonly used radiation and chemo-therapies rely on activation of apoptotic pathways to kill cancer cells, tumor cells which are capable of evading programmed cell death often become resistant to treatment.
• Apoptosis signaling networks are classified as either intrinsic when mediated by death receptor-ligand interactions or extrinsic when mediated by cellular stress and mitochondrial permeabilization. Both pathways ultimately converge on individual Caspases. Once activated, Caspases cleave a number of cell death-related substrates, effecting destruction of the cell.
• Tumor cells have devised a number of strategies to circumvent apoptosis.
• One recently reported molecular mechanism involves the overexpression of members of the IAP (Inhibitor of Apoptosis) protein family.
• IAPs sabotage apoptosis by directly interacting with and neutralizing Caspases.
• the prototype IAPs, XIAP and cIAP have three functional domains referred to as BIR 1, 2 & 3 domains.
• BIR3 domain interacts directly with Caspase 9 and inhibits its ability to bind and cleave its natural substrate, Procaspase 3.
• a proapoptotic mitochondrial protein Smac (also known as DIABLO), is capable of neutralizing XIAP and/or cIAP by binding to a peptide binding pocket (Smac binding site) on the surface of BIR3 thereby precluding interaction between XIAP and/or cIAP and Caspase 9.
• Smac also known as DIABLO
• the present invention relates to therapeutic molecules that bind to the Smac binding pocket thereby promoting apoptosis in rapidly dividing cells.
• Such therapeutic molecules are useful for the treatment of proliferative diseases, including cancer.
• Smac analogs would bind to BIR3 domain of IAPs and will remove the IAP's inhibition of activated Caspase 9 which would then go on to induce apoptosis.
• the present invention relates generally to novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs).
• IAPs Apoptosis Proteins
• the present invention includes novel compounds, novel compositions, methods of their use and methods of their manufacture, where such compounds are generally pharmacologically useful as agents in therapies whose mechanism of action rely on the inhibition of the Smac/IAP interaction, and more particularly useful in therapies for the treatment of proliferative diseases, including cancer.
• the present invention relates to compounds of the formula (I)
• R 1 is H; C 1 -C 4 alkyl; C 1 -C 4 alkenyl; C 1 -C 4 alkynyl or C 3 -C 10 cycloalkyl which are unsubstituted or substituted;
• R 2 is H; C 1 -C 4 alkyl; C 1 -C 4 alkenyl; C 1 -C 4 alkynyl or C 3 -C 10 cycloalkyl which are unsubstituted or substituted;
• R 3 is H; —CF 3 ; —C 2 F 5 ; C 1 -C 4 alkyl; C 1 -C 4 alkenyl; C 1 -C 4 alkynyl; —CH 2 -Z or R 2 and R 3 together with the nitrogen form a het ring;
• Z is H; —OH; F; Cl; —CH 3 ; —CF 3 ; —CH 2 Cl; —CH 2 F or —CH 2 OH;
• R 4 is C 1 -C 16 straight or branched alkyl; C 1 -C 16 alkenyl; C 1 -C 16 alkynyl; or —C 3 -C 10 cycloalkyl; —(CH 2 ) 1-6 -Z 1 ; —(CH 2 ) 0-6 -aryl; and —(CH 2 ) 0-6 -het; wherein alkyl, cycloalkyl and phenyl are unsubstituted or substituted; Z 1 is —N(R 8 )—C(O)—C 1 -C 10 alkyl; —N(R 8 )—C(O)—(CH 2 ) 1-6 —C 3 -C 7 cycloalkyl; —N(R 8 )—C(O)—(CH 2 ) 0-6 -phenyl; —N(R 8 )—C(O)—(CH 2 ) 1-6 -het; —C(O)
• R 8 is H; —CH 3 ; —CF 3 ; —CH 2 OH or —CH 2 Cl;
• R 9 and R 10 are each independently H; C 1 -C 4 alkyl; C 3 -C 7 cycloalkyl; —(CH 2 ) 1-6 —C 3 -C 7 cycloalkyl; —(CH 2 ) 0-6 -phenyl; wherein alkyl, cycloalkyl and phenyl are unsubstituted or substituted, or R 9 and R 10 together with the nitrogen form het; R 5 is H; C 1 -C 10 -alkyl; aryl; phenyl; C 3 -C 7 cycloalkyl; —(CH 2 ) 1-6 —C 3 -C 7 cycloalkyl; —C 1 -C 10 alkyl-aryl; —(CH 2 ) 0-6 —C 3 -C 7 cycloalkyl-(CH 2 ) 0-6 -phenyl; —(CH 2 ) 0-4 CH—((CH 2 ) 1-4
• n 0-5;
• X is —CH or N
• Ra and Rb are independently an O, S, or N atom or C 0-8 alkyl wherein one or more of the carbon atoms in the alkyl chain may be replaced by a heteroatom selected from O, S or N, and where the alkyl may be unsubstituted or substituted;
• Rd is selected from:
• Q is N, O, S, S(O), or S(O) 2 ;
• Ar 1 and Ar 2 are substituted or unsubstituted aryl or het;
• Rf and Rg are each independently H; —C 1 -C 10 alkyl; C 1 -C 10 alkylaryl; —OH; —O—C 1 -C 10 alkyl; —(CH 2 ) 0-6 —C 3 -C 7 cycloalkyl; —O—(CH 2 ) 0-6 -aryl; phenyl; aryl; phenyl-phenyl; —(CH 2 ) 1-6 -het; —O—(CH 2 ) 1-6 -het; —OR 11 ; —C(O)—R 11 ; —C(O)—N(R 11 )(R 12 ); —N(R 11 )(R 12 ); —S—R 11 ; —S(O)—R 11 ; —S(O) 2 —R 11 ; —S(O) 2
• the present invention also related to the use of compound of formula I in the treatment of proliferative diseases, especially those dependent on the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs), or for the manufacture of pharmaceutical compositions for use in the treatment of said diseases, methods of use of compounds of formula (I) in the treatment of said diseases, pharmaceutical preparations comprising compounds of formula (I) for the treatment of said diseases, compounds of formula (I) for use in the treatment of said diseases.
• IAPs Inhibitor of Apoptosis Proteins
• Aryl is an aromatic radical having 6 to 14 carbon atoms, which may be fused or unfused, and which is unsubstituted or substituted by one or more, preferably one or two substituents, wherein the substituents are as described below.
• Preferred “aryl” is phenyl, naphthyl or indanyl.
• Het refers to heteroaryl and heterocyclic rings and fused rings containing aromatic and non-aromatic heterocyclic rings. “Het” is a 5-7 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S, or an 8-12 membered fused ring system including at least one 5-7 membered heterocyclic ring containing 1, 2 or 3 heteroatoms selected from N, O, and S.
• Suitable het substituents include unsubstituted and substituted pyrrolidyl, tetrahydrofuryl, tetrahydrothiofuranyl, piperidyl, piperazyl, tetrahydropyranyl, morphilino, 1,3-diazapane, 1,4-diazapane, 1,4-oxazepane, 1,4-oxathiapane, furyl, thienyl, pyrrole, pyrazole, triazole, 1,2,3-triazole, tetrazolyl, oxadiazole, thiophene, imidazol, pyrrolidine, pyrrolidone, thiazole, oxazole, pyridine, pyrimidine, isoxazolyl, pyrazine, quinoline, isoquinoline, pyridopyrazine, pyrrolopyridine, furopyridine, indole, benzofuran
• the het substituents are unsubstituted or substituted on a carbon atom by halogen, especially fluorine or chlorine, hydroxy, C 1 -C 4 alkyl, such as methyl and ethyl, C 1 -C 4 alkoxy, especially methoxy and ethoxy, nitro, —O—C(O)—C 1 -C 4 alkyl or —C(O)—O—C 1 -C 4 alkyl or on a nitrogen by C 1 -C 4 alkyl, especially methyl or ethyl, —O—C(O)—C 1 -C 4 alkyl or —C(O)—O—C 1 -C 4 alkyl, such as carbomethoxy or carboethoxy.
• halogen especially fluorine or chlorine
• hydroxy C 1 -C 4 alkyl, such as methyl and ethyl, C 1 -C 4 alkoxy, especially methoxy and ethoxy, nitro
• heterocyclic ring is a nitrogen-containing ring, such as aziridine, azetidine, azole, piperidine, piperazine, morphiline, pyrrole, pyrazole, thiazole, oxazole, pyridine, pyrimidine, isoxazolyl, and the like.
• Halogen is fluorine, chlorine, bromine or iodine, especially fluorine and chlorine.
• alkyl includes straight or branched chain alkyl, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl and branched pentyl, n-hexyl and branched hexyl, and the like.
• a “cycloalkyl” group means C 3 to C 10 cycloalkyl having 3 to 8 ring carbon atoms and may be, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl.
• cycloalkyl is cycloheptyl.
• the cycloalkyl group may be unsubstituted or substituted with any of the substituents defined below, preferably halo, hydroxy or C 1 -C 4 alkyl such as methyl.
• the amino acid residues include a residue of a standard amino acid, such as alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine.
• the amino acid residues also include the side chains of uncommon and modified amino acids. Uncommon and modified amino acids are known to those of skill in the art (see for example G. B. Fields, Z.
• the side chain of the amino acid residue contains a derivatizable group, such as COOH, —OH or amino
• the side chain may be derivatized by a substituent that reacts with the derivatizable group.
• a substituent that reacts with the derivatizable group.
• acidic amino acids like aspartic and glutamic acid, or hydroxy substituted side chains, like those of serine or threonine
• the derivative may be a substituent that facilitates transport across a cell membrane.
• any carboxylic acid group in the amino acid residue for example, an alpha carboxylic acid group, may be derivatized as discussed above to form an ester or amide.
• Such lipophillic substituents include a C 6 -C 30 alkyl which is saturated, monounsaturated, polyunsaturated, including methylene-interrupted polyene, phenyl, phenyl which substituted by one or two C 1 -C 8 alkyl groups, C 5 -C 9 cycloalkyl, C 5 -C 9 cycloalkyl which is substituted by one or two C 1 -C 8 alkyl groups, —X 1 -phenyl, —X 1 -phenyl which is substituted in the phenyl ring by one or two C 1 -C 8 alkyl groups, X 1 —C 5 -C 9 cycloalkyl or X 1 —C 5 -C 9 cycloalkyl which is substituted by one or two C 1 -C 8 alkyl groups; where X 1 is C 1 -C 24 alkyl which is saturated, monounsaturated or polyunsaturated and straight or branched
• any of the above defined aryl, het, alkyl, cycloalkyl, or heterocyclic groups may be unsubstituted or independently substituted by up to four, preferably one, two or three substituents, selected from the group consisting of: halo (such as Cl or Br); hydroxy; lower alkyl (such as C 1 -C 3 lower alkyl); lower alkyl which may be substituted with any of the substituents defined herein; lower alkenyl; lower alkynyl; lower alkanoyl; alkoxy (such as methoxy); aryl (such as phenyl or benzyl); substituted aryl (such as fluoro phenyl or methoxy phenyl); amino; mono- or disubstituted amino; amino lower alkyl (such as dimethylamino); acetyl amino; amino lower alkoxy (such as ethoxyamine); nitro; cyano; cyano lower alkyl; carboxy; ester
• R 4 and R 5 together with the N atom form a 3- to 8-membered heterocyclic ring containing 1-4 nitrogen, oxygen or sulfur atoms (e.g. piperazinyl, pyrazinyl, lower alkyl-piperazinyl, pyridyl, indolyl, thiophenyl, thiazolyl, n-methyl piperazinyl, benzothiophenyl, pyrrolidinyl, piperidino or imidazolinyl) where the heterocyclic ring may be substituted with any of the substituents defined herein.
• 1-4 nitrogen, oxygen or sulfur atoms e.g. piperazinyl, pyrazinyl, lower alkyl-piperazinyl, pyridyl, indolyl, thiophenyl, thiazolyl, n-methyl piperazinyl, benzothiophenyl, pyrrolidinyl, piperidino or imid
• alkyl, cycloalkyl, aryl or het groups may be substituted by halogen, carbonyl, thiol, S(O), S(O 2 ), —OH, —SH, —OCH 3 , —SCH 3 , —CN, —SCN or nitro.
• a compound of the invention can exist as a salt form, especially as an acid addition salt or a base addition salt.
• a compound can exist in a salt form, such salt forms are included within the scope of the invention.
• any salt form may be useful in chemical manipulations, such as purification procedures, only pharmaceutically acceptable salts are useful for pharmaceutically products.
• Pharmaceutically acceptable salts include, when appropriate, pharmaceutically acceptable base addition salts and acid addition salts, for example, metal salts, such as alkali and alkaline earth metal salts, ammonium salts, organic amine addition salts, and amino acid addition salts, and sulfonate salts.
• Acid addition salts include inorganic acid addition salts such as hydrochloride, sulfate and phosphate, and organic acid addition salts such as alkyl sulfonate, arylsulfonate, acetate, maleate, fumarate, tartrate, citrate and lactate.
• metal salts are alkali metal salts, such as lithium salt, sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, aluminum salt, and zinc salt.
• ammonium salts are ammonium salt and tetramethylammonium salt.
• organic amine addition salts are salts with morpholine and piperidine.
• amino acid addition salts are salts with glycine, phenylalanine, glutamic acid and lysine.
• Sulfonate salts include mesylate, tosylate and benzene sulfonic acid salts.
• any reference to the compounds hereinbefore and hereinafter especially the compounds of the formula I is to be understood as referring also to the corresponding tautomers of these compounds, especially of compounds of the formula I, tautomeric mixtures of these compounds, especially of compounds of the formula I, or salts of any of these, as appropriate and expedient and if not mentioned otherwise.
• Any asymmetric carbon atom may be present in the (R)-, (S)- or (R,S)-configuration, preferably in the (R)- or (S)-configuration.
• the compounds may thus be present as mixtures of isomers or preferably as pure isomers, preferably as enantiomer-pure diastereomers or pure enantiomers.
• IAPS Apoptosis Proteins
• An embodiment of the present invention relates to compounds of the formula (I)
• R 1 is H; C 1 -C 4 alkyl; C 1 -C 4 alkenyl; C 1 -C 4 alkynyl or cycloalkyl which are unsubstituted or substituted by one or more substituents selected from halogen, —OH, —SH, —OCH 3 , —SCH 3 , —CN, —SCN and nitro;
• R 2 is H; C 1 -C 4 alkyl; C 1 -C 4 alkenyl; C 1 -C 4 alkynyl or cycloalkyl which are unsubstituted or substituted by one or more substituents selected from halogen, —OH, —SH, —OCH 3 , —SCH 3 , —CN, —SCN and nitro;
• R 3 is H; —CF 3 ; —C 2 F 5 ; C 1 -C 4 alkyl; C 1 -C 4 alkenyl; C 1 -C 4 alky
• Z is H; —OH; F; Cl; —CH 3 ; —CF 3 ; —CH 2 Cl; —CH 2 F or —CH 2 OH;
• R 4 is C 1 -C 16 straight or branched alkyl; C 1 -C 16 alkenyl; C 1 -C 16 alkynyl; or —C 3 -C 16 cycloalkyl; —(CH 2 ) 1-6 -Z 1 ; —(CH 2 ) 0-6 -phenyl; and —(CH 2 ) 0-6 -het, wherein alkyl, cycloalkyl and phenyl are unsubstituted or substituted; Z 1 is —N(R 8 )—C(O)—C 1 -C 10 alkyl; —N(R 8 )—C(O)—(CH 2 ) 1-6 —C 3 -C 7 cycloalkyl; —N(R 8 )—C(O)—(CH 2 ) 0-6 -phenyl; —N(R 8 )—C(O)—(CH 2 ) 1-6 -het; —C(O
• R 8 is H, —CH 3 , —CF 3 , —CH 2 OH or —CH 2 Cl;
• R 9 and R 10 are each independently H; C 1 -C 4 alkyl; C 3 -C 7 cycloalkyl; —(CH 2 ) 1-6 —C 3 -C 7 cycloalkyl; —(CH 2 ) 0-6 -phenyl; wherein alkyl, cycloalkyl and phenyl are unsubstituted or substituted, or R 9 and R 10 together with the nitrogen form het;
• R 5 is H; C 1 -C 10 -alkyl; C 3 -C 7 cycloalkyl; —(CH 2 ) 1-6 —C 3 -C 7 cycloalkyl; —C 1 -C 10 alkyl-aryl; —(CH 2 ) 0-6 —C 3 -C 7 cycloalkyl-(CH 2 ) 0-6 -phenyl; —(CH 2 ) 0-4 CH—((CH 2 ) 1-4 -phenyl) 2
• n 0-5;
• X is —CH or N
• Ra and Rb are independently an O, S, or N atom or C 0-8 alkyl wherein one or more of the carbon atoms in the alkyl chain may be replaced by a heteroatom selected from O, S or N, and where the alkyl may be unsubstituted or substituted;
• Rd is selected from:
• Q is N, O, S, S(O), or S(O) 2 ;
• Ar 1 and Ar 2 are substituted or unsubstituted aryl or het;
• Rf and Rg are each independently H; —C 1 -C 10 alkyl; C 1 -C 10 alkylaryl; —OH; —O—C 1 -C 10 alkyl; —(CH 2 ) 0-6 —C 3 -C 7 cycloalkyl; —O—(CH 2 ) 0-6 -aryl; phenyl; aryl; phenyl-phenyl; —(CH 2 ) 1-6 -het; —O—(CH 2 ) 1-6 -het; —OR 11 ; —C(O)—R 11 ; —C(O)—N(R 11 )(R 12 ); —N(R 11 )(R 12 ); —S—R 11 ; —S(O)—R 11 ; —S(O) 2 —R 11 ; —S(O) 2
• a further embodiment the present invention relates to the use of compound of formula I in the treatment of proliferative diseases, especially those dependent on the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs), or for the manufacture of pharmaceutical compositions for use in the treatment of said diseases, methods of use of compounds of formula (I) in the treatment of said diseases, pharmaceutical preparations comprising compounds of formula (I) for the treatment of said diseases, compounds of formula (I) for use in the treatment of said diseases.
• IAPs Inhibitor of Apoptosis Proteins
• One embodiment of the present invention relates to compounds of the formula (I) wherein
• R 1 and R 2 are independently H or substituted or unsubstituted C 1 -C 4 alkyl;
• R 4 is C 1 -C 16 straight or branched alkyl, or C 3 -C 10 cycloalkyl, wherein the alkyl or cycloalkyl may be unsubstituted or substituted;
• R 5 is H; C 1 -C 10 alkyl; C 1 -C 10 alkyl-aryl; —C(O)—(CH 2 ) 0-6 -Phenyl; —(CH 2 ) 0-6 —C(O)-Phenyl; aryl; indanyl; naphthyl or R 5 is a residue of an amino acid, wherein the alkyl or aryl substituents are unsubstituted or substituted;
• U is as shown in structure II:
• n 0-5;
• X is —CH or N
• Ra and Rb are independently an O, S, or N atom or C 0-8 alkyl wherein one or more of the carbon atoms in the alkyl chain may be replaced by a heteroatom selected from O, S or N, and where the alkyl may be unsubstituted or substituted; Rd is selected from
• Q is N, O, S, S(O), or S(O) 2 ;
• Ar 1 and Ar 2 are substituted or unsubstituted aryl or het;
• Rf and Rg are each independently H or substituted or unsubstituted C 0 -C 10 alkyl; C 1 -C 10 alkylaryl; aryl-C 1 -C 10 alkyl; het-C 1 -C 10 alkyl —C(O)—C 1 -C 4 -alkyl-phenyl; —C(O)—C 1 -C 4 -alkyl; —SO 2 —C 1 -C 2 alkyl; —SO 2 —C 1 -C 2 alkylphenyl; —O—C 1 -C 4 -alkyl; D is —C(O)—; C 1-7 alkylene or arylene; —O—, or —S(O) r where r is 0-2; where alkyl, alkylene or arylene which may be unsubstituted or substituted with
• U is a bicyclic saturated or unsaturated ring system, consisting of all carbon skeleton or with one or more heteroatoms such as O, N, S but preferably as shown in structure III:
• any of the ring carbon atoms can be unsubstituted or substituted with any of the substituted defined above for R 6 , R 7 , R 6′ and R 7 ′;
• X is CH or N
• V is O, F 2 , Cl 2 , Br 2 , I 2 , S, YH, H 2 , NH, or C 1 -C 4 alkyl;
• W is —CH, or —N
• the ring atoms may be substituted with substituents independently selected from halo, H, OH, lower alkyl or lower alkoxy, wherein alkyl or alkoxy are unsubstituted or substituted by halogen, OH, lower alkyl or lower alkoxy.
• R 1 and R 3 are preferably methyl or ethyl;
• R 2 is especially H; methyl; ethyl; chloromethyl; dichloromethyl or trifluoromethyl;
• R 4 is —C 1 -C 4 alkyl; —C 3 -C 7 cycloalkyl; —(CH 2 ) 1-6 cycloalkyl; or —(CH 2 ) 0-6 aryl.
• R 4 is particularly ethyl; propyl; isopropyl; t-butyl; cyclopentyl; or cyclohexyl; —CH 2 -cyclopentyl; —CH 2 -cyclohexyl or —CH 2 -phenyl.
• R 5 is —C 1 -C 4 alkyl-phenyl; —C(O)—C 1 -C 4 alkyl-phenyl; —C 1 -C 4 alkyl-C(O)-pheny or aryl; R 5 is particularly phenylmethyl, phenylethyl and phenylpropyl; indanyl, naphthyl; —C(O)—CH 2 -phenyl or —CH 2 —C(O)-phenyl; R 6 and R 7 are H or methyl; U has the structure of formula III:
• any of the ring carbon atoms can be unsubstituted or substituted with any of the substituted defined above for R 6 , R 7 , R 6′ and R 7 ′;
• X is N
• V is O or H 2 ;
• W is —N
• R 1 and R 3 are preferably methyl or ethyl
• R 2 is H
• R 4 is C 1 -C 4 alkyl; C 3 -C 7 cycloalkyl; C 1 -C 7 cycloalkyl-C 1 -C 7 alkyl; phenyl-C 1 -C 7 alkyl or aryl.
• R 4 is particularly methyl; ethyl; butyl; isopropyl; t-butyl; or cyclohexyl; —CH 2 -cyclopentyl; —CH 2 -cyclohexyl; —CH 2 -cyclopropyl; phenyl or —CH 2 -phenyl;
• R 5 is —C 1 -C 4 alkyl-phenyl; —C(O)—C 1 -C 4 alkyl-phenyl; —C 1 -C 4 alkyl-C(O)-pheny or aryl.
• R 5 is particularly phenylethyl; indanyl, naphthyl; —C(O)—CH 2 -phenyl; —CH 2 —C(O)-phenyl or (CF 3 O)phenylethyl;
• R 6 , R′ 6 , R 7 and R′ 7 are H;
• U has the structure of formula III wherein wherein any of the ring carbon atoms can be unsubstituted or substituted with any of the substituted defined above for R 6 , R 7 , R 6′ and R 7 ′;
• X is N
• V is O or H 2 ;
• W is —N
• Another embodiment is directed to a compound of formula (I) wherein
• R 1 and R 3 are preferably methyl or ethyl;
• R 2 is especially H, methyl, ethyl, chloromethyl, dichloromethyl or trifluoromethyl;
• R 4 is C 1 -C 4 alkyl or C 3 -C 7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
• R 5 is H
• X is N
• R 6 , R′ 6 , R 7 , and R′ 7 are H;
• n O
• Rc is H
• Ar 1 and Ar 2 are substituted or unsubstituted phenyl or het particularly tetrazolyl, 1, 2,3-triazole, pyrazole, oxazole, pyrrolyl, triazine, pyrimidine, imidazol, oxadiazol; and and D is C 1 alkyl which may optionally be substituted with halo, especially F.
• Another embodiment is directed to a compound of formula (I) wherein
• R 1 and R 3 are preferably methyl or ethyl;
• R 2 is especially H, methyl, ethyl, chloromethyl, dichloromethyl or trifluoromethyl;
• R 4 is C 1 -C 4 alkyl; C 3 -C 7 cycloalkyl; C 1 -C 7 cycloalkyl-C 1 -C 7 alkyl; phenyl-C 1 -C 7 alkyl or aryl.
• R 4 is particularly methyl, ethyl, butyl, isopropyl, t-butyl, or cyclohexyl; —CH 2 -cyclopentyl, —CH 2 -cyclohexyl; —CH 2 -cyclopropyl; phenyl or —CH 2 -phenyl;
• R 5 is H
• X is N
• R 6 , R′ 6 , R 7 , and R′ 7 are H; or R 6 is —C(O)—C 1 -C 4 alkyl-phenyl and R′ 6 , R 7 , and R′ 7 are H;
• n O
• Rc is H
• Ar 1 and Ar 2 are substituted or unsubstituted phenyl or het, particularly triazine, pyrimidine, pyridine, oxazole, 2,4-difluorophenyl, Cl-phenyl or fluorophenyl; and D is N(Rh), where Rh is H, Me, —CHO, —SO 2 , —C(O), —CHOH, —CF 3 or —SO 2 CH 3 .
• Another embodiment is directed to a compound of formula (I) wherein
• R 1 and R 3 are preferably methyl or ethyl;
• R 2 is especially H, methyl, ethyl, chloromethyl, dichloromethyl or trifluoromethyl;
• R 4 is C 1 -C 4 alkyl; C 3 -C 7 cycloalkyl; C 1 -C 7 cycloalkyl-C 1 -C 7 alkyl; phenyl-C 1 -C 7 alkyl or aryl.
• R 4 is particularly methyl, ethyl, butyl, isopropyl, t-butyl, or cyclohexyl; —CH 2 -cyclopentyl, —CH 2 -cyclohexyl; —CH 2 -cyclopropyl; phenyl or —CH 2 -phenyl;
• R 5 is H
• X is N
• R 6 , R′ 6 , R 7 , and R′ 7 are H;
• n O
• Rc is H
• Ar 1 and Ar 2 are substituted or unsubstituted phenyl or het particularly pyrimidine, pyridine, oxazole, 2-methyloxazole; and D is —O—.
• Another embodiment is directed to a compound of formula (I) wherein
• R 1 and R 3 are preferably methyl or ethyl;
• R 2 is especially H, methyl, ethyl, chloromethyl, dichloromethyl or trifluoromethyl;
• R 4 is C 1 -C 4 alkyl or C 3 -C 7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
• R 5 is H
• X is N
• R 6 , R′ 6 , R 7 , and R′ 7 are H;
• n O
• Rc is H
• Ar 1 and Ar 2 are substituted or unsubstituted phenyl or het; and D is S, S(O), or S(O) 2 .
• Another embodiment is directed to a compound of formula (I) wherein
• R 1 and R 3 are preferably methyl or ethyl;
• R 2 is especially H, methyl, ethyl, chloromethyl, dichloromethyl or trifluoromethyl;
• R 4 is C 1 -C 4 alkyl or C 3 -C 7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
• R 5 is H
• X is N
• R 6 , R′ 6 , R 7 , and R′ 7 are H;
• n O
• Rc is H
• Ar 1 and Ar 2 are substituted or unsubstituted phenyl or het, particularly oxazole, thaizole and ozadiazole; and D is C(O), or 1,3-dioxolane.
• Another embodiment is directed to a compound of formula (I) wherein
• R 1 and R 3 are preferably methyl or ethyl;
• R 2 is especially H, methyl, ethyl, chloromethyl, dichloromethyl or trifluoromethyl;
• R 4 is C 1 -C 4 alkyl or C 3 -C 7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
• R 5 is H or phenyl C 1 -C 10 alkyl such as phenylethyl;
• U has the structure of formula II wherein
• X is N
• R 6 , R′ 6 , R 7 , and R′ 7 are H;
• n O
• Rc and Rd are a heterocyclic ring, particularly pyrrolidine; pyrrolidin-2-one; or pyrrolidin-3-one.
• Another embodiment is directed to a compound of formula (I) wherein
• R 1 and R 3 are preferably methyl or ethyl;
• R 2 is especially H, methyl, ethyl, chloromethyl, dichloromethyl or trifluoromethyl;
• R 4 is C 1 -C 4 alkyl or C 3 -C 7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
• R 5 is H, indanyl or phenyl;
• U has the structure of formula II wherein
• X is N
• R 6 , R′ 6 , R 7 , and R′ 7 are H;
• n O
• Re is C 1 alkyl; and p and q are 0.
• a further embodiment is directed to a compound of formula (I) wherein
• R 1 and R 3 are preferably methyl or ethyl;
• R 2 is especially H, methyl, ethyl, chloromethyl, dichloromethyl or trifluoromethyl;
• R 4 is C 1 -C 4 alkyl or C 3 -C 7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
• R 5 is H, indanyl or phenyl;
• U has the structure of formula II wherein
• X is N
• R 6 , R′ 6 , R 7 , and R′ 7 are H;
• n O
• Re is C 1 alkyl; and R g is H C 1 -C 8 alkyl, methyl, ethyl, hexyl, heptyl, octyl; or CH 2 CF 3 ; or aryl-C 1 -C 4 alkyl particularly phenylethyl, furanylethyl; C 3 -C 7 cycloalkyl particularly cyclohexyl; ethylphenyl; —C(O)—C 1 -C 4 alkyl-phenyl; —C(O)—C 1 -C 4 alkyl; —C 1 -C 4 alkyl-aryl particularly —CH 2 -phenyl; —CH 2 -thiophene, —CH 2 -furan, —CH 2 -pyrrolidinyl, —CH 2 -imidazole, —CH 2 -triazole, —CH 2 -imidazole; and R f is C
• a further embodiment is directed to a compound of formula (I) wherein
• R 1 and R 3 are preferably methyl or ethyl;
• R 2 is especially H, methyl, ethyl, chloromethyl, dichloromethyl or trifluoromethyl;
• R 4 is C 1 -C 4 alkyl or C 3 -C 7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
• R 5 is H, indanyl or phenyl;
• U has the structure of formula II wherein
• X is N
• R 6 , R′ 6 , R 7 , and R′ 7 are H;
• n O
• Re is C 1 alkyl; and R g and R f form a ring selected from het or aryl particularly 2,3,4,5-tetrahydrobenzo[c]azepine; 1,2,3,4 tetrahydroquinoline; indanyl which may be substituted with C 1 -C 4 alkylphenyl
• a further embodiment is directed to a compound of formula (I) wherein
• R 1 and R 3 are preferably methyl or ethyl;
• R 2 is especially H, methyl, ethyl, chloromethyl, dichloromethyl or trifluoromethyl;
• R 4 is C 1 -C 4 alkyl or C 3 -C 7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
• R 5 is phenyl;
• U has the structure of formula II wherein
• X is N
• Q is O, S, S(O) or S(O) 2 ;
• R 6 , R′ 6 , R 7 , and R′ 7 are H;
• n O
• Re is C 1 alkyl; q is 0;
• Rc is H
• R f is C 2 alkyl.
• a further embodiment is directed to a compound of formula (I) wherein
• R 1 and R 3 are preferably methyl or ethyl;
• R 2 is especially H, methyl, ethyl, chloromethyl, dichloromethyl or trifluoromethyl;
• R 4 is C 1 -C 4 alkyl or C 3 -C 7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
• R 5 is phenyl;
• U has the structure of formula II wherein
• X is N
• R 6 , R′ 6 , R 7 , and R′ 7 are H;
• n O
• Rc is H
• R f is OC 1 alkyl.
• R 3 and R 4 have the stereochemistry indicated in formula IV, with the definitions of the variable substituents and preferences described herein above also applying to compounds having the stereochemistry indicated in formula IV.
• R 1 and R 3 are preferably methyl or ethyl;
• R 2 is H, methyl, ethyl, or substituted methyl especially chloromethyl, dichloromethyl and trifluoromethyl; preferably R 2 is H or unsubstituted methyl;
• R 4 is C 1 -C 4 alkyl or C 3 -C 7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
• R 5 is —C 1 -C 4 -alkyl-phenyl, particularly phenylmethyl, phenylethyl and phenylpropyl, indanyl, naphthyl; and
• R 6 and R 7 are H or methyl.
• R 6 , R 7 , R 6′ , and R 7′ is H. If one of R 6 , R 7 , R 6′ , and R 7′ is other than H, it is especially hydroxyl or phenoxy.
• KOTMS is defined as potassium trimethysilanoate.
• Step A This step involves the formation of an aziridine ring via standard base mediated conditions.
• Step B This step involves the formation of a secondary amine via the reaction of an alkyl bromide with excess amine in the presence of a base.
• Step C This step involves the coupling of a secondary amine with an activated derivative of the aziridine methyl ester to form an amide substituted aziridine.
• Step D This step involves the intramolecular cycloaddition of the aziridine to the tethered alkene through a thermally accessible azomethine ylide intermediate.
• Step E This step involves the reduction of the amide to an amine via standard reduction conditions employing DIBAL-H.
• Step F This step involves the removal of the benzylic protecting group using standard palladium conditions under a hydrogen atmosphere.
• Step G This step involves coupling of the scaffold with a t-Boc protected natural or unnatural amino acid using standard peptide coupling conditions followed by the removal of the t-Boc group with TFA.
• Step H This step involves the coupling of the amine generated in the preceding step with a t-Boc protected or tertiary natural or unnatural amino acid using standard peptide coupling conditions followed by the removal of the t-Boc group with TFA if applicable. The product is then purified by high-performance liquid chromatography (HPLC).
• HPLC high-performance liquid chromatography
• the compounds of the present invention are useful for treating proliferative diseases.
• the present invention further relates to a method of treating a proliferative disease which comprises administering a therapeutically effective amount of a compound of the invention to a mammal, preferably a human, in need of such treatment.
• a proliferative disease is mainly a tumor disease (or cancer) (and/or any metastases).
• the inventive compounds are particularly useful for treating a tumor which is a breast cancer, genitourinary cancer, lung cancer, gastrointestinal cancer, epidermoid cancer, melanoma, ovarian cancer, pancreas cancer, neuroblastoma, head and/or neck cancer or bladder cancer, or in a broader sense renal, brain or gastric cancer; in particular (i) a breast tumor; an epidermoid tumor, such as an epidermoid head and/or neck tumor or a mouth tumor; a lung tumor, for example a small cell or non-small cell lung tumor; a gastrointestinal tumor, for example, a colorectal tumor; or a genitourinary tumor, for example, a prostate tumor (especially a hormone-refractory prostate tumor); or (ii) a proliferative disease that is refractory to the treatment with other chemotherapeutics; or (iii)
• a proliferative disease may furthermore be a hyperproliferative condition such as leukemias, hyperplasias, fibrosis (especially pulmonary, but also other types of fibrosis, such as renal fibrosis), angiogenesis, psoriasis, atherosclerosis and smooth muscle proliferation in the blood vessels, such as stenosis or restenosis following angioplasty.
• a hyperproliferative condition such as leukemias, hyperplasias, fibrosis (especially pulmonary, but also other types of fibrosis, such as renal fibrosis), angiogenesis, psoriasis, atherosclerosis and smooth muscle proliferation in the blood vessels, such as stenosis or restenosis following angioplasty.
• metastasis in the original organ or tissue and/or in any other location are implied alternatively or in addition, whatever the location of the tumor and/or metastasis.
• the inventive compound is selectively toxic or more toxic to rapidly proliferating cells than to normal cells, particularly in human cancer cells, e.g., cancerous tumors, the compound has significant antiproliferative effects and promotes differentiation, e.g., cell cycle arrest and apoptosis.
• the compounds of the present invention may be administered alone or in combination with other anticancer agents, such as compounds that inhibit tumor angiogenesis, for example, the protease inhibitors, epidermal growth factor receptor kinase inhibitors, vascular endothelial growth factor receptor kinase inhibitors and the like; cytotoxic drugs, such as antimetabolites, like purine and pyrimidine analog antimetabolites; antimitotic agents like microtubule stabilizing drugs and antimitotic alkaloids; platinum coordination complexes; anti-tumor antibiotics; alkylating agents, such as nitrogen mustards and nitrosoureas; endocrine agents, such as adrenocorticosteroids, androgens, anti-androgens, estrogens, anti-estrogens, aromatase inhibitors, gonadotropin-releasing hormone agonists and somatostatin analogues and compounds that target an enzyme or receptor that is overexpressed and/or otherwise involved a specific metabolic pathway that is upregulated in the tumor cell
• the present invention further relates to a method of promoting apoptosis in rapidly proliferating cells, which comprises contacting the rapidly proliferating cells with an effective apoptosis promoting amount of a non-naturally-occurring compound that binds to the Smac binding site of XIAP and/or cIAP proteins.
• the non-naturally-occurring compound a compound of present formula I or IV.
• the present invention further relates to a method of treating or inhibiting myeloma, especially multiple myeloma.
• myeloma as used herein relates to a tumor composed of cells of the type normally found in the bone marrow.
• multiple myeloma as used herein means a disseminated malignant neoplasm of plasma cells which is characterized by multiple bone marrow tumor foci and secretion of an M component (a monoclonal immunoglobulin fragment), associated with widespread osteolytic lesions resulting in bone pain, pathologic fractures, hypercalcaemia and normochromic normocytic anaemia. Multiple myeloma is incurable by the use of conventional and high dose chemotherapies.
• the invention relates to a method of treating myeloma, especially myeloma which is resistant to conventional chemotherapy.
• the invention relates also to pharmaceutical compositions comprising a compound of formula I, to their use in the therapeutic (in a broader aspect of the invention also prophylactic) treatment or a method of treatment of a kinase dependent disease, especially the preferred diseases mentioned above, to the compounds for said use and to pharmaceutical preparations and their manufacture, especially for said uses.
• the present invention also relates to pro-drugs of a compound of formula I that convert in vivo to the compound of formula I as such. Any reference to a compound of formula I is therefore to be understood as referring also to the corresponding pro-drugs of the compound of formula I, as appropriate and expedient.
• pharmacologically acceptable compounds of the present invention may be present in or employed, for example, for the preparation of pharmaceutical compositions that comprise an effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, as active ingredient together or in admixture with one or more inorganic or organic, solid or liquid, pharmaceutically acceptable carriers (carrier materials).
• compositions according to the invention are those for enteral, such as nasal, rectal or oral, or parenteral, such as intramuscular or intravenous, administration to warm-blooded animals (especially a human), that comprise an effective dose of the pharmacologically active ingredient, alone or together with a significant amount of a pharmaceutically acceptable carrier.
• the dose of the active ingredient depends on the species of warm-blooded animal, the body weight, the age and the individual condition, individual pharmacokinetic data, the disease to be treated and the mode of administration.
• the invention relates also to a method of treatment for a disease that responds to inhibition of a protein kinase and/or a proliferative disease, which comprises administering a (against the mentioned diseases) prophylactically or especially therapeutically effective amount of a compound of formula I according to the invention, or a tautomer thereof or a pharmaceutically acceptable salt thereof, especially to a warm-blooded animal, for example a human, that, on account of one of the mentioned diseases, requires such treatment.
• the dose of a compound of the formula I or a pharmaceutically acceptable salt thereof to be administered to warm-blooded animals preferably is from approximately 3 mg to approximately 10 g, more preferably from approximately 10 mg to approximately 1.5 g, most preferably from about 100 mg to about 1000 mg/person/day, divided preferably into 1-3 single doses which may, for example, be of the same size. Usually, children receive half of the adult dose.
• compositions comprise from approximately 1% to approximately 95%, preferably from approximately 20% to approximately 90%, active ingredient.
• Pharmaceutical compositions according to the invention may be, for example, in unit dose form, such as in the form of ampoules, vials, suppositories, dragées, tablets or capsules.
• compositions of the present invention are prepared in a manner known per se, for example by means of conventional dissolving, lyophilizing, mixing, granulating or confectioning processes.
• a compound of the formula I may also be used to advantage in combination with other antiproliferative agents.
• antiproliferative agents include, but are not limited to aromatase inhibitors; antiestrogens; topoisomerase I inhibitors; topoisomerase II inhibitors; microtubule active agents; alkylating agents; histone deacetylase inhibitors; compounds which induce cell differentiation processes; cyclooxygenase inhibitors; MMP inhibitors; mTOR inhibitors; antineoplastic antimetabolites; platin compounds; compounds targeting/decreasing a protein or lipid kinase activity and further anti-angiogenic compounds; compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase; gonadorelin agonists; anti-androgens; methionine aminopeptidase inhibitors; bisphosphonates; biological response modifiers; antiproliferative antibodies; heparanase inhibitors; inhibitors of Ras oncogenic isoforms; tel
• aromatase inhibitor as used herein relates to a compound which inhibits the estrogen production, i.e. the conversion of the substrates androstenedione and testosterone to estrone and estradiol, respectively.
• the term includes, but is not limited to steroids, especially atamestane, exemestane and formestane and, in particular, non-steroids, especially aminoglutethimide, roglethimide, pyridoglutethimide, trilostane, testolactone, ketokonazole, vorozole, fadrozole, anastrozole and letrozole.
• Exemestane can be administered, e.g., in the form as it is marketed, e.g.
• AROMASIN Formestane can be administered, e.g., in the form as it is marketed, e.g. under the trademark LENTARON. Fadrozole can be administered, e.g., in the form as it is marketed, e.g. under the trademark AFEMA. Anastrozole can be administered, e.g., in the form as it is marketed, e.g. under the trademark ARIMIDEX. Letrozole can be administered, e.g., in the form as it is marketed, e.g. under the trademark FEMARA or FEMAR. Aminoglutethimide can be administered, e.g., in the form as it is marketed, e.g. under the trademark ORIMETEN.
• a combination of the invention comprising a chemotherapeutic agent which is an aromatase inhibitor is particularly useful for the treatment of hormone receptor positive tumors, e.g. breast tumors.
• antiestrogen as used herein relates to a compound which antagonizes the effect of estrogens at the estrogen receptor level.
• the term includes, but is not limited to tamoxifen, fulvestrant, raloxifene and raloxifene hydrochloride.
• Tamoxifen can be administered, e.g., in the form as it is marketed, e.g. under the trademark NOLVADEX.
• Raloxifene hydrochloride can be administered, e.g., in the form as it is marketed, e.g. under the trademark EVISTA.
• Fulvestrant can be formulated as disclosed in U.S. Pat. No.
• 4,659,516 or it can be administered, e.g., in the form as it is marketed, e.g. under the trademark FASLODEX.
• a combination of the invention comprising a chemotherapeutic agent which is an antiestrogen is particularly useful for the treatment of estrogen receptor positive tumors, e.g. breast tumors.
• anti-androgen as used herein relates to any substance which is capable of inhibiting the biological effects of androgenic hormones and includes, but is not limited to, bicalutamide (CASODEX), which can be formulated, e.g. as disclosed in U.S. Pat. No. 4,636,505.
• CASODEX bicalutamide
• gonadorelin agonist as used herein includes, but is not limited to abarelix, goserelin and goserelin acetate. Goserelin is disclosed in U.S. Pat. No. 4,100,274 and can be administered, e.g., in the form as it is marketed, e.g. under the trademark ZOLADEX. Abarelix can be formulated, e.g. as disclosed in U.S. Pat. No. 5,843,901.
• topoisomerase I inhibitor includes, but is not limited to topotecan, gimatecan, irinotecan, camptothecian and its analogues, 9-nitrocamptothecin and the macromolecular camptothecin conjugate PNU-166148 (compound A1 in WO99/17804).
• Irinotecan can be administered, e.g. in the form as it is marketed, e.g. under the trademark CAMPTOSAR.
• Topotecan can be administered, e.g., in the form as it is marketed, e.g. under the trademark HYCAMTIN.
• topoisomerase II inhibitor includes, but is not limited to the anthracyclines such as doxorubicin (including liposomal formulation, e.g. CAELYX), daunorubicin, epirubicin, idarubicin and nemorubicin, the anthraquinones mitoxantrone and losoxantrone, and the podophillotoxines etoposide and teniposide.
• Etoposide can be administered, e.g. in the form as it is marketed, e.g. under the trademark ETOPOPHOS.
• Teniposide can be administered, e.g. in the form as it is marketed, e.g.
• Doxorubicin can be administered, e.g. in the form as it is marketed, e.g. under the trademark ADRIBLASTIN or ADRIAMYCIN.
• Epirubicin can be administered, e.g. in the form as it is marketed, e.g. under the trademark FARMORUBICIN.
• Idarubicin can be administered, e.g. in the form as it is marketed, e.g. under the trademark ZAVEDOS.
• Mitoxantrone can be administered, e.g. in the form as it is marketed, e.g. under the trademark NOVANTRON.
• microtubule active agent relates to microtubule stabilizing, microtubule destabilizing agents and microtublin polymerization inhibitors including, but not limited to taxanes, e.g. paclitaxel and docetaxel, vinca alkaloids, e.g., vinblastine, especially vinblastine sulfate, vincristine especially vincristine sulfate, and vinorelbine, discodermolides, cochicine and epothilones and derivatives thereof, e.g. epothilone B or D or derivatives thereof.
• Paclitaxel may be administered e.g. in the form as it is marketed, e.g. TAXOL.
• Docetaxel can be administered, e.g., in the form as it is marketed, e.g. under the trademark TAXOTERE.
• Vinblastine sulfate can be administered, e.g., in the form as it is marketed, e.g. under the trademark VINBLASTIN R.P.
• Vincristine sulfate can be administered, e.g., in the form as it is marketed, e.g. under the trademark FARMISTIN.
• Discodermolide can be obtained, e.g., as disclosed in U.S. Pat. No. 5,010,099.
• Epothilone derivatives which are disclosed in WO 98/10121, U.S. Pat. No. 6,194,181, WO 98/25929, WO 98/08849, WO 99/43653, WO 98/22461 and WO 00/31247.
• Epothilone A and/or B are also included.
• alkylating agent includes, but is not limited to, cyclophosphamide, ifosfamide, melphalan or nitrosourea (BCNU or Gliadel).
• Cyclophosphamide can be administered, e.g., in the form as it is marketed, e.g. under the trademark CYCLOSTIN.
• Ifosfamide can be administered, e.g., in the form as it is marketed, e.g. under the trademark HOLOXAN.
• histone deacetylase inhibitors or “HDAC inhibitors” relates to compounds which inhibit the histone deacetylase and which possess antiproliferative activity. This includes compounds disclosed in WO 02/22577, especially N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide, N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide and pharmaceutically acceptable salts thereof. It further especially includes Suberoylanilide hydroxamic acid (SAHA).
• SAHA Suberoylanilide hydroxamic acid
• anti-plastic antimetabolite includes, but is not limited to, 5-Fluorouracil or 5-FU, capecitabine, gemcitabine, DNA demethylating agents, such as 5-azacytidine and decitabine, methotrexate and edatrexate, and folic acid antagonists such as pemetrexed.
• Capecitabine can be administered, e.g., in the form as it is marketed, e.g. under the trademark XELODA.
• Gemcitabine can be administered, e.g., in the form as it is marketed, e.g. under the trademark GEMZAR.
• the monoclonal antibody trastuzumab which can be administered, e.g., in the form as it is marketed, e.g. under the trademark HERCEPTIN.
• platinum compound as used herein includes, but is not limited to, carboplatin, cis-platin, cisplatinum and oxaliplatin.
• Carboplatin can be administered, e.g., in the form as it is marketed, e.g. under the trademark CARBOPLAT.
• Oxaliplatin can be administered, e.g., in the form as it is marketed, e.g. under the trademark ELOXATIN.
• compound “compounds targeting/decreasing a protein or lipid kinase activity and further anti-angiogenic compounds” as used herein includes, but is not limited to: protein tyrosine kinase and/or serine and/or threonine kinase inhibitors or lipid kinase inhibitors, e.g.:
• FGF-Rs fibroblast growth factor-receptors
• IGF-IR insulin-like growth factor receptor I
• Trk receptor tyrosine kinase family compounds which target, decrease or inhibit the activity of the Trk receptor tyrosine kinase family
• c-Met receptor compounds targeting, decreasing or inhibiting the activity of the c-Met receptor
• PKC protein kinase C
• Raf Raf family of serine/threonine kinases, members of the MEK, SRC, JAK, FAK, PDK and Ras/MAPK family members, or PI(3) kina
• examples of further compounds include e.g. UCN-01, safingol, BAY 43-9006, Bryostatin 1, Perifosine; Ilmofosine; RO 318220 and RO 320432; GO 6976; Isis 3521; LY333531/LY379196; isochinoline compounds such as those disclosed in WO 00/09495; FTIs; PD184352 or QAN697 (a P13K inhibitor); g) compounds targeting, decreasing or inhibiting the activity of a protein-tyrosine kinase, such as imatinib mesylate (GLIVEC/GLEEVEC) or tyrphostin.
• GLIVEC/GLEEVEC imatinib mesylate
• a tyrphostin is preferably a low molecular weight (Mr ⁇ 1500) compound, or a pharmaceutically acceptable salt thereof, especially a compound selected from the benzylidenemalonitrile class or the S-arylbenzenemalonirile or bisubstrate quinoline class of compounds, more especially any compound selected from the group consisting of Tyrphostin A23/RG-50810; AG 99; Tyrphostin AG 213; Tyrphostin AG 1748; Tyrphostin AG 490; Tyrphostin B44; Tyrphostin B44 (+) enantiomer; Tyrphostin AG 555; AG 494; Tyrphostin AG 556, AG957 and adaphostin (4- ⁇ [(2,5-dihydroxyphenyl)methyl]amino ⁇ -benzoic acid adamantyl ester; NSC 680410, adaphostin); and h) compounds targeting, decreasing or inhibiting the activity of the epidermal growth factor family of receptor
• EGF receptor ErbB2, ErbB3 and ErbB4 or bind to EGF or EGF related ligands, and are in particular those compounds, proteins or monoclonal antibodies generically and specifically disclosed in WO 97/02266, e.g. the compound of ex. 39, or in EP 0 564 409, WO 99/03854, EP 0520722, EP 0 566 226, EP 0 787 722, EP 0 837 063, U.S. Pat. No. 5,747,498, WO 98/10767, WO 97/30034, WO 97/49688, WO 97/38983 and, especially, WO 96/30347 (e.g.
• WO 96/33980 e.g. compound ZD 1839
• WO 95/03283 e.g. compound ZM105180
• trastuzumab HERCEPTIN
• cetuximab Iressa
• Tarceva Tarceva
• CI-1033 EKB-569
• GW-2016 E1.1, E2.4, E2.5, E6.2, E6.4, E2.11, E6.3 or E7.6.3, and 7H-pyrrolo-[2,3-d]pyrimidine derivatives which are disclosed in WO 03/013541.
• anti-angiogenic compounds include compounds having another mechanism for their activity, e.g. unrelated to protein or lipid kinase inhibition e.g. thalidomide (THALOMID) and TNP-470.
• TAALOMID thalidomide
• TNP-470 TNP-470.
• Compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase are e.g. inhibitors of phosphatase 1, phosphatase 2A, PTEN or CDC25, e.g. okadaic acid or a derivative thereof.
• Compounds which induce cell differentiation processes are e.g. retinoic acid, ⁇ - ⁇ - or ⁇ -tocopherol or ⁇ - ⁇ - or ⁇ -tocotrienol.
• cyclooxygenase inhibitor includes, but is not limited to, e.g. Cox-2 inhibitors, 5-alkyl substituted 2-arylaminophenylacetic acid and derivatives, such as celecoxib (CELEBREX), rofecoxib (VIOXX), etoricoxib, valdecoxib or a 5-alkyl-2-arylaminophenylacetic acid, e.g. 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenyl acetic acid, lumiracoxib.
• Cox-2 inhibitors such as celecoxib (CELEBREX), rofecoxib (VIOXX), etoricoxib, valdecoxib or a 5-alkyl-2-arylaminophenylacetic acid, e.g. 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenyl acetic acid, lumiracoxib.
• mTOR inhibitors relates to compounds which inhibit the mammalian target of rapamycin (mTOR) and which possess antiproliferative activity such as sirolimus (Rapamune®), everolimus (CerticanTM), CCI-779 and ABT578.
• bisphosphonates as used herein includes, but is not limited to, etridonic, clodronic, tiludronic, pamidronic, alendronic, ibandronic, risedronic and zoledronic acid.
• Etridonic acid can be administered, e.g., in the form as it is marketed, e.g. under the trademark DIDRONEL.
• Clodronic acid can be administered, e.g., in the form as it is marketed, e.g. under the trademark BONEFOS.
• titaniumudronic acid can be administered, e.g., in the form as it is marketed, e.g. under the trademark SKELID.
• “Pamidronic acid” can be administered, e.g. in the form as it is marketed, e.g. under the trademark AREDIATM.
• “Alendronic acid” can be administered, e.g., in the form as it is marketed, e.g. under the trademark FOSAMAX.
• “Ibandronic acid” can be administered, e.g., in the form as it is marketed, e.g. under the trademark BONDRANAT.
• “Risedronic acid” can be administered, e.g., in the form as it is marketed, e.g. under the trademark ACTONEL.
• “Zoledronic acid” can be administered, e.g. in the form as it is marketed, e.g. under the trademark ZOMETA.
• heparanase inhibitor refers to compounds which target, decrease or inhibit heparin sulphate degradation.
• the term includes, but is not limited to, PI-88.
• biological response modifier refers to a lymphokine or interferons, e.g. interferon ⁇ .
• inhibitor of Ras oncogenic isoforms e.g. H-Ras, K-Ras, or N-Ras
• H-Ras, K-Ras, or N-Ras refers to compounds which target, decrease or inhibit the oncogenic activity of Ras e.g. a “farnesyl transferase inhibitor”, e.g. L-744832, DK8G557 or R115777 (Zarnestra).
• telomerase inhibitor refers to compounds which target, decrease or inhibit the activity of telomerase.
• Compounds which target, decrease or inhibit the activity of telomerase are especially compounds which inhibit the telomerase receptor, e.g. telomestatin.
• methionine aminopeptidase inhibitor refers to compounds which target, decrease or inhibit the activity of methionine aminopeptidase.
• Compounds which target, decrease or inhibit the activity of methionine aminopeptidase are e.g. bengamide or a derivative thereof.
• proteasome inhibitor refers to compounds which target, decrease or inhibit the activity of the proteasome.
• Compounds which target, decrease or inhibit the activity of the proteasome include e.g. PS-341 and MLN 341.
• matrix metalloproteinase inhibitor or (“MMP inhibitor”) as used herein includes, but is not limited to collagen peptidomimetic and nonpeptidomimetic inhibitors, tetracycline derivatives, e.g. hydroxamate peptidomimetic inhibitor batimastat and its orally bioavailable analogue marimastat (BB-2516), prinomastat (AG3340), metastat (NSC 683551) BMS-279251, BAY 12-9566, TAA211, MMI270B or AAJ996.
• MMP inhibitor matrix metalloproteinase inhibitor
• agents used in the treatment of hematologic malignancies includes, but is not limited to FMS-like tyrosine kinase inhibitors e.g. compounds targeting, decreasing or inhibiting the activity of Flt-3; interferon, 1-b-D-arabinofuransylcytosine (ara-c) and bisulfan; and ALK inhibitors e.g. compounds which target, decrease or inhibit anaplastic lymphoma kinase.
• FMS-like tyrosine kinase inhibitors e.g. compounds targeting, decreasing or inhibiting the activity of Flt-3
• interferon 1-b-D-arabinofuransylcytosine (ara-c) and bisulfan
• ALK inhibitors e.g. compounds which target, decrease or inhibit anaplastic lymphoma kinase.
• kits which target, decrease or inhibit the activity of Flt-3 are especially compounds, proteins or antibodies which inhibit Flt-3, e.g. PKC412, midostaurin, a staurosporine derivative, SU11248 and MLN518.
• HSP90 inhibitors includes, but is not limited to, compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90; degrading, targeting, decreasing or inhibiting the HSP90 client proteins via the ubiquitin proteasome pathway.
• Compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90 are especially compounds, proteins or antibodies which inhibit the ATPase activity of HSP90 e.g., 17-allylamino, 17-demethoxygeldanamycin (17AAG), a geldanamycin derivative; other geldanamycin related compounds; radicicol and HDAC inhibitors.
• antiproliferative antibodies includes, but is not limited to trastuzumab (HerceptinTM), Trastuzumab-DM1, erlotinib (TarcevaTM), bevacizumab (AvastinTM), rituximab (Rituxan®), PRO64553 (anti-CD40) and 2C4 Antibody.
• antibodies is meant e.g. intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies formed from at least 2 intact antibodies, and antibodies fragments so long as they exhibit the desired biological activity.
• compounds of formula I can be used in combination with standard leukemia therapies, especially in combination with therapies used for the treatment of AML.
• compounds of formula I can be administered in combination with e.g. farnesyl transferase inhibitors and/or other drugs useful for the treatment of AML, such as Daunorubicin, Adriamycin, Ara-C, VP-16, Teniposide, Mitoxantrone, Idarubicin, Carboplatinum and PKC412.
• a compound of the formula I may also be used to advantage in combination with known therapeutic processes, e.g., the administration of hormones or especially radiation.
• a compound of formula I may in particular be used as a radiosensitizer, especially for the treatment of tumors which exhibit poor sensitivity to radiotherapy.
• ком ⁇ онент there is meant either a fixed combination in one dosage unit form, or a kit of parts for the combined administration where a compound of the formula I and a combination partner may be administered independently at the same time or separately within time intervals that especially allow that the combination partners show a cooperative, e.g. synergistic, effect, or any combination thereof.
• the organic layer is dried and concentrated under vacuum.
• the residue is purified by flash chromatography (silica gel; Hexane/EtOAc 1:9) to provide a yellow oil.
• the yellow oil is dissolved in dichloromethane (20 mL), TFA (10 mL) is added and the mixture is stirred at room temperature for 3 h.
• the mixture is concentrated and the residue is dissolved in dichloromethane (100 mL) and neutralized with saturated sodium bicarbonate.
• the solution is extracted with dichloromethane (3 ⁇ 50 mL).
• the organic extracts are combined, dried and concentrated under vacuum to provide 1.75 g (79% two steps) of the title compound which is used in next step without further purification or characterization.
• But-3-enyl-((S)-1-phenyl-ethyl)-amine (A): To a solution of S-( ⁇ )-1-phenyl ethylamine (15.75 g, 130 mmol) in 150 mL of DMF at 0° C. is added K 2 CO 3 (53.9 g, 390 mmol) in small portions. After stirring at 0° C. for 10 min, 4-bromobutene (13.5 g, 100 mmol) is added dropwise and followed by NaI (58.5 g, 390 mmol) in small portions. The reaction mixture, a white suspension, is heated to 95° C. and stirred overnight/16 hrs.
• D (2S,3R)-3-But-3-enyl-1-((S)-1-phenyl-ethyl)-pyrrolidine-2-carboxylic acid ethyl ester (1.0 g, 3.32 mmol) is dissolved in EtOH (10 mL) with HCl (0.5 mL, 37%), and cooled to ⁇ 70° C. Ozone gas is bubbled though the solution for about 10 min or until the solution is turned very light blue color.
• the residue is purified by flash chromatography (silica gel; Hexane/EtOAc 4:1) to provide a yellow oil.
• the yellow oil is dissolved in dichloromethane (20 mL), TFA (10 mL) is added and the mixture is stirred at room temperature for 3 h.
• the mixture is concentrated and the residue is dissolved in dichloromethane (100 mL) and neutralized with saturated sodium bicarbonate.
• the solution is extracted with dichloromethane (3 ⁇ 50 mL).
• the organic extracts are combined, dried and concentrated under vacuum to provide 1.04 g (68% two steps) of the title compound E which is used in the next step without further purification or characterization.
• Compound 32 is prepared as follows:
• an ELISA and a cell based assays are utilized.
• the remaining GST-BIR3 fusion protein is monitored by ELISA assay involving first, incubation with goat anti-GST antibodies followed by washing and incubation with alkaline phosphatase conjugated anti-goat antibodies. Signal is amplified using Attophos (Promega) and read with Cytoflour Ex 450 nm/40 and Em 580 nm.
• IC 50 s correspond to concentration of compound which displaces half of GST-BIR3 signal.
• the IC 50 for non-biotinylated Smac is 400 nM.
• the IC 50 values of compounds listed in Table 1 in the described ELISA assays ranged from 0.005-10 ⁇ M.
• the ability of compounds to inhibit tumor cell growth in vitro is monitored using the CellTiter 96® AQ ueous Non-Radioactive Cell Proliferation Assay (Promega).
• This assay is composed of solutions of a novel tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] and an electron coupling reagent (phenazine methosulfate) PMS.
• MTS is bioreduced by cells into a formazan product, the absorbance of which is measured at 490 nm.
• the conversion of MTS into the aqueous soluble formazan product is accomplished by dehydrogenase enzymes found in metabolically active cells.
• the quantity of formazan product as measured by the amount of 490 nm absorbance is directly proportional to the number of living cells in culture.
• the IC 50 values of compounds listed in Table 1 in the described cell assays ranged from 0.005-50 ⁇ M.
• Tablets 1 Comprising Compounds of the Formula (I)
• Tablets comprising, as active ingredient, 50 mg of any one of the compounds of formula (I) mentioned in the preceding Examples 9-194 of the following composition are prepared using routine methods:
• composition Active Ingredient 50 mg Wheat starch 60 mg Lactose 50 mg Colloidal silica 5 mg Talcum 9 mg Magnesium stearate 1 mg Total 175 mg
• Manufacture The active ingredient is combined with part of the wheat starch, the lactose and the colloidal silica and the mixture pressed through a sieve. A further part of the wheat starch is mixed with the 5-fold amount of water on a water bath to form a paste and the mixture made first is kneaded with this paste until a weakly plastic mass is formed.
• the dry granules are pressed through a sieve having a mesh size of 3 mm, mixed with a pre-sieved mixture (1 mm sieve) of the remaining corn starch, magnesium stearate and talcum and compressed to form slightly biconvex tablets.
• Tablets comprising, as active ingredient, 100 mg of any one of the compounds of formula (I) of Examples 9-194 are prepared with the following composition, following standard procedures:
• composition Active Ingredient 100 mg Crystalline lactose 240 mg Avicel 80 mg PVPPXL 20 mg Aerosil 2 mg Magnesium stearate 5 mg Total 447 mg
• Manufacture The active ingredient is mixed with the carrier materials and compressed by means of a tabletting machine (Korsch EKO, Stempel sacrificer 10 mm).
• Capsules comprising, as active ingredient, 100 mg of any one of the compounds of formula (I) given in Examples 9-194, of the following composition are prepared according to standard procedures:
• Active Ingredient 100 mg Avicel 200 mg PVPPXL 15 mg Aerosil 2 mg Magnesium stearate 1.5 mg Total 318.5 mg
• Manufacturing is done by mixing the components and filling them into hard gelatine capsules, size 1.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Vascular Medicine (AREA)
• Oncology (AREA)
• Diabetes (AREA)
• Endocrinology (AREA)
• Urology & Nephrology (AREA)
• Hematology (AREA)
• Dermatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Plural Heterocyclic Compounds (AREA)
• Pyrrole Compounds (AREA)
• Peptides Or Proteins (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (3)

Applications Claiming Priority (3)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=34962601

Family Applications (4)

Family Applications After (3)

Country Status (32)

Cited By (1)

Families Citing this family (139)

Citations (13)

Family Cites Families (40)

• 2005
  • 2005-04-06 AR ARP050101365A patent/AR048927A1/es not_active Application Discontinuation
  • 2005-04-06 ES ES05716547T patent/ES2394441T3/es active Active
  • 2005-04-06 TW TW094110874A patent/TWI417092B/zh not_active IP Right Cessation
  • 2005-04-06 KR KR1020087021449A patent/KR20080083220A/ko not_active Application Discontinuation
  • 2005-04-06 CN CN2005800186137A patent/CN1964970B/zh not_active Expired - Fee Related
  • 2005-04-06 SG SG200902372-2A patent/SG152225A1/en unknown
  • 2005-04-06 EP EP10172398A patent/EP2253614B1/en active Active
  • 2005-04-06 CA CA2560162A patent/CA2560162C/en active Active
  • 2005-04-06 JP JP2007506718A patent/JP4691549B2/ja not_active Expired - Fee Related
  • 2005-04-06 US US10/594,413 patent/US20080242658A1/en not_active Abandoned
  • 2005-04-06 EP EP09153639A patent/EP2065368A1/en not_active Withdrawn
  • 2005-04-06 KR KR1020067023240A patent/KR100892185B1/ko active IP Right Grant
  • 2005-04-06 PE PE2009001297A patent/PE20110102A1/es active IP Right Grant
  • 2005-04-06 MY MYPI20051543A patent/MY165401A/en unknown
  • 2005-04-06 SI SI200531639T patent/SI2253614T1/sl unknown
  • 2005-04-06 EP EP05716547A patent/EP1735307B1/en active Active
  • 2005-04-06 US US11/099,941 patent/US7419975B2/en active Active
  • 2005-04-06 RU RU2006139010/04A patent/RU2425838C2/ru active
  • 2005-04-06 BR BRPI0509721-5A patent/BRPI0509721A/pt not_active Application Discontinuation
  • 2005-04-06 ES ES10172398T patent/ES2396195T3/es active Active
  • 2005-04-06 AU AU2005231956A patent/AU2005231956B2/en not_active Ceased
  • 2005-04-06 DK DK10172398.9T patent/DK2253614T3/da active
  • 2005-04-06 PE PE2005000384A patent/PE20060166A1/es active IP Right Grant
  • 2005-04-06 RS RS20120557A patent/RS52545B/en unknown
  • 2005-04-06 WO PCT/EP2005/003619 patent/WO2005097791A1/en active Application Filing
  • 2005-04-06 PT PT101723989T patent/PT2253614E/pt unknown
  • 2005-04-06 ME MEP-2012-557A patent/ME02125B/me unknown
  • 2005-04-06 NZ NZ549925A patent/NZ549925A/en not_active IP Right Cessation
  • 2005-04-06 PL PL10172398T patent/PL2253614T3/pl unknown
• 2006
  • 2006-09-14 ZA ZA200607696A patent/ZA200607696B/en unknown
  • 2006-09-14 IL IL178104A patent/IL178104A/en active IP Right Grant
  • 2006-09-29 EC EC2006006893A patent/ECSP066893A/es unknown
  • 2006-10-06 TN TNP2006000323A patent/TNSN06323A1/en unknown
  • 2006-10-30 MA MA29422A patent/MA28630B1/fr unknown
  • 2006-11-06 NO NO20065114A patent/NO20065114L/no not_active Application Discontinuation
• 2007
  • 2007-06-06 HK HK07106025.9A patent/HK1100930A1/xx not_active IP Right Cessation
• 2010
  • 2010-04-27 JP JP2010102494A patent/JP2010215635A/ja not_active Withdrawn
• 2011
  • 2011-07-08 US US13/178,946 patent/US8207183B2/en active Active
• 2012
  • 2012-04-26 US US13/456,274 patent/US8338440B2/en active Active
  • 2012-12-12 HR HRP20121023TT patent/HRP20121023T1/hr unknown
  • 2012-12-13 JP JP2012272668A patent/JP2013049733A/ja active Pending
  • 2012-12-19 CY CY20121101238T patent/CY1113511T1/el unknown

Patent Citations (13)

Also Published As